Stocksigma LogoStocksigma Logo

Bharat Parenterals Subsidiary Innoxel Commences Commercial Supply to the US Market

Bharat Parenterals’ 55.9% subsidiary, Innoxel Lifesciences, commenced commercial supply to the US with its first CMO product launched on 20th Oct'26

Bharat Parenterals Subsidiary Innoxel Commences Commercial Supply to the US Market

Bharat Parenterals Ltd · Press Release · 21 Oct 2026, 6:59 pm

Bharat Parenterals Subsidiary Innoxel Commences Commercial Supply to the US Market Bharat Parenterals’ 55.9% subsidiary, Innoxel Lifesciences, commenced commercial supply to the US with its first CMO product launched on 20th Oct'26. Manufactured at its Vadodara facility—holding US FDA EIR (Jul'25) and EU-GMP certification (Mar'26)—this marks the first of two planned FY27 CMO launches. Commercial supply introduces recurring revenue alongside licensing income, which drove all ₹72.4 crore of FY26 revenue (₹17.1 crore upfront, ₹55.3 crore milestone-linked). Innoxel signed 23 deals in FY26 (48 total since inception) and actively partners with 19 entities across the US, EU, and India.

Original exchange filing (PDF)

More announcements from Bharat Parenterals Ltd

All Bharat Parenterals Ltd announcements